MEDIA RELEASE

Senores Pharmaceuticals, Inc. announces the approval and launch of Deferiprone Tablets USP, 500 mg & 1000 mg which will be marketed by Dr. Reddy's Laboratories Inc. in the US market

Atlanta, USA / Ahmedabad, India, December 11, 2025 – Senores Pharmaceuticals, Inc. today announced the launch of Deferiprone Tablets USP, 500 mg & 1000 mg, which is bioequivalent and therapeutically equivalent to Ferriprox Tablets of Chiesi USA, Inc. in the U.S. market. The product will be marketed by Dr. Reddy's Laboratories Inc.

"We are pleased to advance our growth with the launch of a limited-competition product. This aligns with our strategic focus on identifying and entering a niche, under-penetrated generic formulations with an opportunity to serve the unmet needs in healthcare" stated Swapnil Shah, Managing Director, Senores Pharmaceuticals Limited.

Deferiprone Tablets, 500 mg & 1000 mg brand and generic products, had U.S. sales of approximately $70 million MAT for the twelve months ending in October 2025 according to symphony.

About Senores Pharmaceuticals Limited:

Senores Pharmaceuticals Limited (together with its subsidiaries "**Senores**") is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies' current portfolio includes 46 ANDAs and 133 strengths along with a pipeline of 22 ANDAs and 52 strengths In the CMO/CDMO vertical 8 ANDAs and 24 products permitted for distribution in the USA along with a pipeline of 16 ANDAs and 57 strengths. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets, catering to more than 40 countries. The company currently has approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 394 product registrations and 824 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients ("**API**").

Senores has 2 manufacturing facilities for formulations – one in Atlanta, US which is USFDA approved and DEA, TAA & BAA compliant for controlled substances and government supplies & other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites (1 in the USA and 2 in India).

Safe Harbor Statement:

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential project characteristics, project potential and target dates for project related issues are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.

For more information, please contact:

Company: Senores Pharmaceuticals Limited
CIN: L24290GJ2017PLC100263

Mr. Deval Shah
Email: investors@senorespharma.com

For updates and specific queries, please visit
www.senorespharma.com

Investor Relations: Strategic Growth Advisors
CIN: U74140MH2010PTC204285

Mr. Sagar Shroff / Mr. Tanay Shah
M: +91 98205 19303 / +91 98333 91899
E-mail: sagar.shroff@sgapl.net / tanay.shah@sgapl.net
For updates and specific queries, please visit
www.sgapl.net